Lyra Therapeutics Inc

NASDAQ:LYRA  
4.90
-0.64 (-11.55%)
Products

Lyra Therapeutics Announces Positive Outcome Of End-of-Phase 2 Meeting With The FDA For LYR-210

Published: 06/08/2021 21:51 GMT
Lyra Therapeutics Inc (LYRA) - Lyra Therapeutics Announces Positive Outcome of End-of-phase 2 Meeting With the FDA for Lyr-210 for the Treatment of Chronic Rhinosinusitis.
Lyra Therapeutics - Lyra, FDA Established Key Elements of Phase 3 Program to Support a 505(b)(2) NDA for Lyr-210 for Treatment of Crs.